AI
Wednesday, December 19, 2012 7:22:56 AM
Roy your odds of correct prediction for cancer vaccines just improved to 50-50 (sipuleucel-t down stimuvax up) 
OK we know this is a long shot after non-stop at IA2. But all is not lost according to Francis Shaperd
Quote
“It is disappointing that the START trial did not meet its primary endpoint, in particular for patients suffering from NSCLC,“ said Dr. Frances Shepherd, Scott Taylor Chair in Lung Cancer Research at the Princess Margaret Hospital and Professor of Medicine at the University of Toronto, Canada, and Coordinating Investigator of the START trial. “However, notable treatment effects were observed in certain subgroups of patients and warrant further investigation of L-BLP25.”
End quote
Hopefully we will see some data at ASCO.
OK we know this is a long shot after non-stop at IA2. But all is not lost according to Francis Shaperd
Quote
“It is disappointing that the START trial did not meet its primary endpoint, in particular for patients suffering from NSCLC,“ said Dr. Frances Shepherd, Scott Taylor Chair in Lung Cancer Research at the Princess Margaret Hospital and Professor of Medicine at the University of Toronto, Canada, and Coordinating Investigator of the START trial. “However, notable treatment effects were observed in certain subgroups of patients and warrant further investigation of L-BLP25.”
End quote
Hopefully we will see some data at ASCO.
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
